CRP and rheumatoid arthritis: During 1-year follow-up, RA patients with baseline myeloid-stromal pathotype showed the poorest therapeutic response with the lowest rate of Boolean remission (21.1% vs. 35.9% vs. 53.8%, p =0.032, Figure 3C), and the highest DAS28-CRP (2.6 (2.0, 3.6) vs. 2.1 (1.5, 3.1) vs. 2.6 (1.6, 3.1), p = 0.039, Supplementary Figure S2) at 3 months.